Serotonin pp 146-151 | Cite as

5-HT1A Receptors and Cardiovascular Control

  • J. R. Fozard
  • A. K. Mir
  • A. G. Ramage
Part of the Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology book series (SSNIC)


Substantial evidence implicates 5-hydroxytryptamine (5-HT) neurones in the control of cardiovascular function. The precise nature of that role remains, however, undefined, a reflection in part of the plurality of 5-HT receptors and, in particular, the absence until recently of truly selective agonists and antagonists for these sites (Bradley et al., 1986). However, a number of compounds are now recognized to have both high affinity and a certain selectivity for the 5-HT1A subtype of high-affinity [3H]-5-HT binding sites, including 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), dipropyl-5-carboxamidotryptamine (DP-5-CT), MDL 72832, ipsapirone and flesinoxan (Middlemiss and Fozard, 1983; Dompert et al., 1985; Hagenbach et al., 1986; Bevan et al., 1986; Fozard et al., 1987a). Described below are the results from experiments in rats and cats in which these compounds have been used to explore the role of the putative 5-HT1Areceptor in cardiovascular control.


Vagal Tone Cardiovascular Control Block Block Vasodepressor Effect Atropine Methonitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bevan, P., Ramage, A. G. and Wouters, W. (1986). Investigation of the effects of DU 29373 on the cardiovascular system of the anaesthetized cat. Br. J. Pharmacol., 89, 506PGoogle Scholar
  2. Bradley, P. B., Engel, G., Feniuk, W., Fozard, J. R., Humphrey, P. P. A., Middlemiss, D. N., Mylecharane, E. J., Richardson, B. P. and Saxena, P. R. (1986). Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology, 25, 563–576Google Scholar
  3. Dalton, D. W., Feniuk, W. and Humphrey, P. P. A. (1986). An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and Doca-Salt hypertensive rats. J. Auton. Pharmacol., 6, 219–229Google Scholar
  4. Dompert, D. U., Glaser, T. and Traber, J. (1985). [3H]-TVX Q 7821: identification of 5-HT1 binding sites as targets for a novel putative anxiolytic. Naunyn-Schmiedeberg’s Arch. Pharmacol., 328, 467–470Google Scholar
  5. Fozard, J. R. and Mir, A. K. (1987). Are 5-HT1A receptors involved in the antihypertensive effects of urapidil? Br. J. Pharmacol., 90, 24PGoogle Scholar
  6. Fozard, J. R., Hibert, M., Kidd, E. J., Middlemiss, D. N., Mir, A. K. and Tricklebank, M. D. (1987a). MDL 72832: a potent, selective and stereospecific ligand for 5-HT1A receptors. Br. J. Pharmacol., 90, 273PGoogle Scholar
  7. Fozard, J. R., Mir, A. K. and Middlemiss, D. N. (1987b). The cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J. Cardiovasc. Pharmacol., 9, 328–347Google Scholar
  8. Gradin, K., Petterson, A., Hedner, T. and Persson, B. (1985). Acute administration of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a selective 5-HT receptor agonist, causes a biphasic blood pressure response and a bradycardia in the normotensive Sprague-Dawley rat and the spontaneously hypertensive rat. J. Neural Transm., 62, 305–319Google Scholar
  9. Hagenbach, A., Hoyer, D., Kalkman, H. O. and Seiler, M. P. (1986). N,N-Dipropyl-5-carboxamidotryptamine (DP-5CT), an extremely potent and selective 5-HT1A agonist. Br. J. Pharmacol., 87, 136PGoogle Scholar
  10. Heuring, R. E. and Peroutka, S. J. (1987). Characterization of a novel [3H]-5-hydroxytryptamine binding site subtype in bovine brain membranes. J. Neurosci., 7, 894–903Google Scholar
  11. Hoyer, D. (1989). In Fozard, J. R. (Ed.), The Peripheral Actions of 5-Hydroxytryptamine, Oxford University Press, Oxford, pp. 72–99Google Scholar
  12. Middlemiss, D. N. and Fozard, J. R. (1983). 8-Hydroxy-2-(di-n-propylamino) tetralin discriminates between subtypes of the 5-HT recognition site. Eur. J. Pharmacol., 90, 150–153Google Scholar
  13. Mir, A. K. and Fozard, J. R. (1987). Cardiovascular effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). In Dourish, C. T., Ahlenius, S. and Hutson, P. H. (Eds), Brain 5-HT1A Receptors, Ellis Horwood, Chichester, pp. 120–134Google Scholar
  14. Mir, A. K., Hibert, M. and Fozard, J. R. (1987). In Nobin, A., Owman, Ch. and Arneklo-Nobin, B. (Eds), Neuronal Messengers in Vascular Function, Elsevier, Amsterdam, pp. 21–29Google Scholar
  15. Ramage, A. G. (1984). The effect of propranolol and other antihypertensive drugs on preganglionic sympathetic nerve activity. Neuropharmacology, 23, 43–48Google Scholar
  16. Ramage, A. G. and Fozard, J. R. (1987). Evidence that the putative 5-HT1Areceptor agonists, 8-OH-DPAT and ipsapirone have a central hypotensive action that differs from that of clonidine in anaesthetised cats. Eur. J. Pharmacol., 138, 179–191Google Scholar
  17. Sanders, K. H. and Jurna, I. (1985). Effects of urapidil, clonidine, prazosin and propranolol on autonomic nerve activity, blood pressure and heart rate in anaesthetized rats and cats. Eur. J. Pharmacol., 110, 181–190Google Scholar

Copyright information

© The editors and contributors 1989

Authors and Affiliations

  • J. R. Fozard
    • 1
  • A. K. Mir
    • 1
  • A. G. Ramage
    • 2
  1. 1.Preclinical Research DepartmentSandoz LimitedBaselSwitzerland
  2. 2.Academic Department of PharmacologyRoyal Free Hospital Medical SchoolHampstead, LondonUK

Personalised recommendations